General Newsroom Hero 1920x480 (4:1)
Our Work

Latham & Watkins Advises Corvus Pharmaceuticals in its Public Offering of Common Stock

February 12, 2021
A corporate team advises the clinical-stage biopharmaceutical company in the offering.

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, has announced the pricing of an underwritten public offering of 8,571,429 shares of its common stock at a price to the public of US$3.50 per share, for gross proceeds of US$30 million before deducting estimated underwriting discounts and commissions and estimated offering expenses payable by Corvus. All of the shares are being offered by Corvus. In addition, Corvus has granted the underwriters of the offering a 30-day option to purchase up to an additional 1,285,714 shares of common stock at the public offering price, less underwriting discounts and commissions.

Latham & Watkins LLP represents Corvus Pharmaceuticals on the offering with a corporate deal team led by Bay Area partner Miles Jennings, with associates Michelle Lu and Amanda Dillon. Advice was also provided on tax matters by Los Angeles partner Samuel Weiner, with associate Janet Hsu; and on regulatory matters by Washington, D.C. partner Elizabeth Richards, with associate Chad Jennings.